M27-A3

This document addresses the selection and preparation of antifungal agents; implementation and interpretation of test procedures; and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute  
Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
www.clsi.org  
standard@clsi.org

Volume 28  Number 14

John H. Rex, MD, FACP
Barbara D. Alexander, MD, MHS
David Andes, MD
Beth Arthington-Skaggs, PhD
Steven D. Brown, PhD
Vishnu Chaturvedi, PhD
Mahmoud A. Ghannoum, MSc, PhD
Ana Espinel-Ingroff, PhD
Cynthia C. Knapp, MS
Luis Ostrosky-Zeichner, MD, FACP
Michael A. Pfaller, MD
Daniel J. Sheehan, PhD
Thomas J. Walsh, MD

Abstract

Clinical and Laboratory Standards Institute document M27-A3—Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Third Edition describes a method for testing the susceptibility of antifungal agents to yeast that cause invasive fungal infections, including Candida spp. (and Candida glabrata), and Cryptococcus neoformans. Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of quality control procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in quality control is also presented.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org
Contents

Abstract.................................................................................................................................................. i
Committee Membership........................................................................................................................ iii
Foreword................................................................................................................................................ vii
Updated Information in This Edition................................................................................................. viii

1 Scope.................................................................................................................................................. 1
2 Introduction........................................................................................................................................ 1
3 Standard Precautions.......................................................................................................................... 1
4 Definitions ......................................................................................................................................... 1
5 Indications for Performing Susceptibility Tests............................................................................... 2
6 Antifungal Agents.............................................................................................................................. 3
   6.1 Source ......................................................................................................................................... 3
   6.2 Weighing Antifungal Powders .................................................................................................. 3
   6.3 Preparing Stock Solutions .......................................................................................................... 4
   6.4 Number of Concentrations Tested ............................................................................................. 5
   6.5 Selection of Antifungal Agents for Routine Testing and Reporting .......................................... 5
7 Test Procedures................................................................................................................................... 6
   7.1 Broth Medium ............................................................................................................................... 6
   7.2 Preparing Diluted Antifungal Agents .......................................................................................... 6
   7.3 Inoculum Preparation ................................................................................................................. 7
   7.4 Inoculating RPMI-1640 Medium ................................................................................................. 8
   7.5 Incubation .................................................................................................................................... 8
   7.6 Reading Results ........................................................................................................................... 8
   7.7 Interpretation of Results ............................................................................................................. 8
   7.8 Broth Microdilution Modifications .............................................................................................. 10
   7.9 Trailing Growth and the Impact of Time of Reading ................................................................... 12
   7.10 Other Modifications ................................................................................................................. 12
8 Quality Control ................................................................................................................................... 12
   8.1 Purpose ....................................................................................................................................... 12
   8.2 QC Responsibilities ..................................................................................................................... 12
   8.3 Selecting Reference Strains ....................................................................................................... 13
   8.4 Storing Reference Strains .......................................................................................................... 13
   8.5 Routine Use of Reference Strains ............................................................................................... 14
   8.6 Batch of Medium and Lot of Plasticware Control ...................................................................... 15
   8.7 QC Frequency ............................................................................................................................. 15
   8.8 Other Control Procedures .......................................................................................................... 16
   8.9 QC Strains ...................................................................................................................................... 16

References............................................................................................................................................... 17

Appendix A. RPMI 1640 Medium........................................................................................................... 19
Appendix B. McFarland 0.5 Barium Sulfate Turbidity Standard............................................................ 20
Summary of Delegate Comments and Committee Responses............................................................. 21
The Quality Management System Approach ........................................................................................ 24
Related CLSI Reference Materials ...................................................................................................... 25
Foreword

With the increased incidence of systemic fungal infections and the growing number of antifungal agents, laboratory aids to guide in the selection of antifungal therapy have gained greater attention. In 1982, the CLSI Area Committee for Microbiology formed the Subcommittee on Antifungal Susceptibility Testing. In 1985, this subcommittee published its first report\(^1\) in which the results of a questionnaire and a small collaborative study were presented. These results are summarized as follows:

- Approximately 20% of the responding CLSI membership whose hospitals had greater than 200 beds was performing antifungal testing.
- Most testing involved broth dilution methodology.
- Most strains tested were *Candida albicans* or other species of yeasts.
- Most centers tested only a few isolates per year.
- Agreement in minimal inhibitory concentration (MIC) results among several laboratories that participated in a collaborative study was unacceptably low.

Based on these findings, the subcommittee concluded that it would be useful to work toward a more reproducible reference testing procedure.

Agreement already existed regarding several elements of the procedure. To facilitate further analysis of various test conditions, the reference method should be a broth macrodilution procedure. Because of examples of drug antagonism by some complex media for certain antifungals, the subcommittee restricted its interest only to fully defined synthetic media. Drug stock solution preparation and dilution procedures previously developed for antibacterial testing procedures were adopted with minor modifications.

Despite agreement in some areas, other factors required additional data to be resolved. These included inoculum preparation; inoculum size; choice among several synthetic media; temperature of incubation; duration of incubation; and end-point definition. These factors were the focus of a series of collaborative studies.\(^2\)\(^-\)\(^5\) As a result, agreement within the subcommittee was achieved on all of the factors and led to the publication of M27-P in 1992. In the next four years (1992-1996), reference MIC ranges were established for two quality control strains for the available antifungal agents,\(^6\)\(^,\)\(^7\) and broth microdilution procedures paralleling the broth macrodilution reference procedure became available.\(^5\)\(^,\)\(^8\)\^-\(^10\) This information was included in a revised standard in 1995 (M27-T). In further revising the document, the subcommittee focused its attention on developing relevant breakpoints for available antifungal agents,\(^11\) included in M27-A (1997). Since then, the subcommittee has developed 24- and 48-hour reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.\(^12\) The results of these studies are included in the current M27-A3 and M27-S3 (Informational Supplement)\(^13\) documents.

**Key Words**

antifungal, broth macrodilution, broth microdilution, susceptibility testing, yeasts
Updated Information in This Edition

Definitions (Section 4)

Modified definition:
Minimal inhibitory concentration (MIC)

Added definition:
Antimicrobial susceptibility test interpretive category
Quality control

Additional Section

Indications for performing susceptibility tests (Section 5)
Time of reading (Section 7.8.1)

Data Inclusion/Exclusion

Established numerical scale criteria for visual comparison of the amount of growth in the control tubes (Section 7.6)

Established guide for reading and interpretation of results of Echinocandin antifungals (Sections 7.6.3 and 7.7.8)

Expanded recommendations and explanations on acceptable time of reading for antifungal agents when growth is adequate (Sections 7.8.1 and 7.9)

Tables

All related tables were updated and compiled separately as M27-S3, Informational Supplement instead of a document Appendix. Updates on each table include:

Table 1: Interpretive Guidelines for In Vitro Susceptibility Testing of Candida spp.
Added new column on “nonsusceptible (NS)” criteria for interpretive guidelines.

Added breakpoints criteria for the following antifungal agents:
Anidulafungin
Caspofungin
Micafungin
Voriconazole (first added in M27-S2, published February 2006)

Provided additional footnote information for Flucytosine, Anidulafungin, Caspofungin, and Micafungin.

Table 2: Solvents and Diluents for Preparation of Stock Solutions of Antifungal Agents
Added solvents and diluents recommendations for the following antifungal agents:
Anidulafungin
Caspofungin
Micafungin

Table 5: Recommended 48-Hour MIC Limits for Two Quality Control and Four Reference Strains for Broth Macrodilution Procedures
Added information on Issatchenka orientalis as the known sexual form of Candida krusei.

Table 6: Recommended 24- and 48-Hour MIC Limits for Two Quality Control Strains for Broth Microdilution
Added the following antifungal agents:
Anidulafungin (first added in M27-S2, published February 2006)
Caspofungin (first added in M27-S2, published February 2006)
Micafungin

1 Scope

This document describes a method for testing the susceptibility to antifungal agents of yeasts, including Candida spp. and Cryptococcus neoformans, that cause infections. This method has not been extensively validated for the yeast forms of dimorphic fungi, such as Blastomyces dermatitidis or Histoplasma capsulatum variety capsulatum.

The subcommittee has focused on developing relevant breakpoints for available antifungal agents,¹¹ and reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.¹² Interpretive minimal inhibitory concentration (MIC) breakpoints and MIC ranges for quality control (QC) isolates are summarized in an Informational Supplement¹³ to this document.

2 Introduction

The broth macrodilution method described in this document is intended for testing yeasts that cause invasive infections. These yeasts encompass Candida spp. (including Candida glabrata) and C. neoformans. The method has not been used in studies of the yeast forms of dimorphic fungi, such as B. dermatitidis and/or H. capsulatum variety capsulatum. Moreover, testing filamentous fungi (moulds) introduces several additional problems in standardization not addressed by the current procedure. A reference method for broth dilution antifungal susceptibility testing of filamentous fungi has been developed and is now available as CLSI document M38.¹⁴¹⁶

M27-A3 is a “reference” standard developed through a consensus process to facilitate the agreement among laboratories in measuring the susceptibility of yeasts to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also will result in interlaboratory agreement within specified ranges. For example, broth microdilution methods, described in this document, have been configured to produce results paralleling those obtained by the broth macrodilution reference method. Such methods might have particular advantages, such as ease of performance, economy, or more rapid results; therefore, their development could be highly desirable. To the extent that any method produces concordant results with this reference method, it would be considered to be in conformity with M27-A3.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention.¹⁷ For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.¹⁸

4 Definitions

antibiogram – overall profile of antimicrobial susceptibility results of a microbial species to a battery of antimicrobial agents.

¹⁸Clinical and Laboratory Standards Institute. All rights reserved.
antimicrobial susceptibility test interpretive category – 1) a classification based on an in vitro response of an organism to an antimicrobial agent at levels corresponding to blood or tissue levels attainable with usually prescribed doses of that agent; 2) susceptible antimicrobial susceptibility test interpretive category – a category that implies that isolates are inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection; 3) susceptible-dose dependent antimicrobial susceptibility test interpretive category – the “susceptible-dose dependent” category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal possible blood level achieved; 4) intermediate antimicrobial susceptibility test interpretive category – the “intermediate” category includes isolates with antimicrobial agent MICs that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates and/or available data do not permit them to be clearly categorized as either “susceptible” or “resistant.” This category also includes a buffer zone, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations; 5) resistant antimicrobial susceptibility test interpretive category – a category that implies that isolates are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules; 6) nonsusceptible – this category is used for organisms that currently have only a susceptible interpretive category, but not intermediate or resistant interpretive categories (ie, susceptible-only interpretive category) and is often given to new antimicrobial agents for which no resistant isolates have yet been encountered.

minimal inhibitory concentration (MIC) – the lowest concentration of an antimicrobial agent that causes a specified reduction in visible growth in an agar or broth dilution susceptibility test. The magnitude of reduction in visible growth is assessed using the following numerical scale: 0, optically clear; 1, slightly hazy; 2, prominent decrease (~50%) in visible growth; 3, slight reduction in visible growth; and 4, no reduction in visible growth.

quality control – the operational techniques that are used to ensure accuracy and reproducibility.

5 Indications for Performing Susceptibility Tests

Susceptibility testing is indicated for any organism that contributes to an infectious process warranting antimicrobial chemotherapy if its susceptibility cannot be reliably predicted from knowledge of the organism’s identity. Susceptibility tests are most often indicated when the causative organism is thought to belong to a species capable of exhibiting resistance to commonly used antimicrobial agents. Mechanisms of resistance include alteration of drug targets, altered drug uptake or efflux, and absence of microbial enzymes to metabolize drug to active form. Some organisms have predictable susceptibility to antimicrobial agents, and empiric therapy for these organisms is widely accepted. Susceptibility tests are also important in studies of the epidemiology of resistance and in studies of new antimicrobial agents.

Isolated colonies of each type of organism that may be pathogenic should be selected from primary agar plates and tested for susceptibility. Identification procedures are often performed at the same time. Mixtures of different types of microorganisms should not be tested on the same susceptibility test plate or panel. The practice of conducting susceptibility tests directly with clinical material (eg, normally sterile body fluids and urine) should be avoided except in clinical emergencies when the direct gram stain suggests a single pathogen. When testing has been carried out directly with the clinical material, results should be reported as preliminary, and the susceptibility test must be repeated using the standardized methodology.

When the nature of the infection is not clear and the specimen contains mixed growth or normal flora, in which the organisms probably bear little relationship to the infectious process being treated, susceptibility tests are often unnecessary, and the results may be misleading.

The MIC obtained using a dilution test may tell a physician the concentration of antimicrobial agent required at the site of infection to inhibit the infecting organism. The MIC, however, does not represent an
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI/NCCLS document HS1—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Documents & Records
- Organization
- Personnel
- Equipment
- Purchasing & Inventory
- Process Control
- Information Management
- Occurrence Management
- Process Improvement
- Assessments—External & Internal
- Customer Service
- Facilities & Safety

M27-A3 addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI/NCCLS document GP26—Application of a Quality Management System Model for Laboratory Services defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

M27-A3 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI/NCCLS document HS1—A Quality Management System Model for Health Care.
Related CLSI Reference Materials∗


M11-A7  Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard—Seventh Edition (2007). This standard provides reference methods for the determination of minimal inhibitory concentrations (MICs) of anaerobic bacteria by agar dilution and broth microdilution.

M23-A2  Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline—Second Edition (2001). This document addresses the required and recommended data needed for the selection of appropriate interpretative standards and quality control guidelines for new antimicrobial agents.

M24-A  Antimycobacterial Susceptibility Testing; Approved Standard (2003). This standard provides protocols and related quality control parameters and interpretive criteria for the susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes.

M29-A3  Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on U.S. regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

M38-A  Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard (2002). This document addresses the selection of antifungal agents; preparation of antifungal stock solutions and dilutions for testing; implementation and interpretation of test procedures; and quality control requirements for susceptibility testing of filamentous fungi (moulds) that cause invasive fungal infections.

∗ Proposed-level documents are being advanced through the Clinical and Laboratory Standards Institute consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we’re adding initiatives to bring even more value to our members and customers.

Shop Our Online Products
Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.

Visit the CLSI U Education Center
Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.

Find Membership Opportunities
See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.

For more information, visit www.clsi.org today.